From: FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysis
Parameter | Number of samples | Positive FGFR1 amplification number (%) | P value |
---|---|---|---|
Age | 478 | Â | 0.027 |
   <50 years | 152 | 7 (4.6) |  |
   ≥50 years | 346 | 35 (10.1) |  |
Grade | 478 | Â | Not significant |
   1 | 116 | 10 (8.6) |  |
   2 | 141 | 12 (8.5) |  |
   3 | 221 | 20 (9.0) |  |
Size | 478 | Â | Not significant |
   ≥1.5 cm | 311 | 30 (9.6) |  |
   >1.5 cm | 167 | 12 (7.2) |  |
Lymph node stage | 475 | Â | Not significant |
   N0 | 322 | 28 (8.7) |  |
   N1 | 110 | 9 (8.2) |  |
   N2 | 43 | 4 (9.3) |  |
Nottingham Prognostic Index | 475 | Â | Not significant |
   Good | 175 | 14 (8.0) |  |
   Moderate | 239 | 21 (8.8) |  |
   Poor | 61 | 6 (9.8) |  |
Distant metastasis | 478 | Â | 0.050 |
   No | 394 | 30 (7.6) |  |
   Definite | 84 | 12 (14.3) |  |
Vascular invasion | 467 | Â | Not significant |
   No | 337 | 27 (8.0) |  |
   Yes | 130 | 14 (10.8) |  |
Oestrogen receptor | 453 | Â | Not significant |
   Negative | 140 | 10 (7.1) |  |
   Positive | 313 | 27 (8.6) |  |
Progesterone receptor | 449 | Â | 0.084 |
   Negative | 206 | 22 (10.7) |  |
   Positive | 243 | 15 (6.2) |  |
HER2 | 445 | Â | 0.043 |
   Negative | 259 | 28 (10.8) |  |
   Positive | 186 | 10 (5.4) |  |
Androgen receptor | 415 | Â | Not significant |
   Negative | 188 | 18 (9.6) |  |
   Positive | 227 | 13 (5.7) |  |
Cytokeratin 7/8 | 467 | Â | Not significant |
   Negative | 167 | 17 (10.2) |  |
   Positive | 300 | 24 (8.0) |  |
Cytokeratin 18 | 396 | Â | Not significant |
   Negative | 116 | 7 (6.0) |  |
   Positive | 280 | 23 (8.2) |  |
Cytokeratin 19 | 464 | Â | Not significant |
   Negative | 95 | 10 (10.5) |  |
   Positive | 369 | 30 (8.1) |  |
Cytokeratin 5/6 | 465 | Â | Not significant |
   Negative | 350 | 34 (9.7) |  |
   Positive | 115 | 6 (5.2) |  |
Cytokeratin 14 | 458 | Â | Not significant |
   Negative | 357 | 33 (9.2) |  |
   Positive | 101 | 6 (5.9) |  |
Epidermal growth factor receptor | 351 | Â | Not significant |
   Negative | 292 | 26 (8.9) |  |
   Positive | 59 | 3 (5.1) |  |
Basal markers [27] | 455 | Â | Not significant |
   Negative | 311 | 31 (10.0) |  |
   Positive | 144 | 8 (5.6) |  |
Nielsen groups [28] | 396 | Â | Not significant |
   HER2 | 39 | 3 (7.7) |  |
   Basal-like | 55 | 3 (5.5) |  |
   Luminal | 302 | 26 (8.6) |  |